Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma
Thalidomide (Thal) is a drug with antiangiogenic, anti-inflammatory, and immunomodulatory properties that was found to inhibit the production of tumor necrosis factor-α (TNF-α) in vitro. We studied single nucleotide polymorphisms at positions −308 and −238 of the TNF-α gene promoter and measured the...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[15 September 2002]
|
| In: |
Blood
Year: 2002, Jahrgang: 100, Heft: 6, Pages: 2263-2265 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.V100.6.2263 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.V100.6.2263 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0006497120510343 
|
| Verfasserangaben: | Kai Neben, Joannis Mytilineos, Thomas M. Moehler, Astrid Preiss, Alwin Kraemer, Anthony D. Ho, Gerhard Opelz, and Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1780935943 | ||
| 003 | DE-627 | ||
| 005 | 20220820092255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211210s2002 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.V100.6.2263 |2 doi | |
| 035 | |a (DE-627)1780935943 | ||
| 035 | |a (DE-599)KXP1780935943 | ||
| 035 | |a (OCoLC)1341436107 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Neben, Kai |d 1969- |e VerfasserIn |0 (DE-588)120842181 |0 (DE-627)080920470 |0 (DE-576)292411774 |4 aut | |
| 245 | 1 | 0 | |a Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma |c Kai Neben, Joannis Mytilineos, Thomas M. Moehler, Astrid Preiss, Alwin Kraemer, Anthony D. Ho, Gerhard Opelz, and Hartmut Goldschmidt |
| 246 | 3 | 3 | |a Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma |
| 264 | 1 | |c [15 September 2002] | |
| 300 | |b Diagramme | ||
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.12.2021 | ||
| 520 | |a Thalidomide (Thal) is a drug with antiangiogenic, anti-inflammatory, and immunomodulatory properties that was found to inhibit the production of tumor necrosis factor-α (TNF-α) in vitro. We studied single nucleotide polymorphisms at positions −308 and −238 of the TNF-α gene promoter and measured the corresponding TNF-α cytokine levels in 81 patients (pts) with refractory and relapsed multiple myeloma (MM) who were treated with Thal. In myeloma pts carrying the TNF-238A allele (n = 8), we found a correlation with higher pretreatment TNF-α levels in peripheral blood (P = .047). After Thal administration, this TNF-238A group had a prolonged 12-month progression-free and overall survival of 86% and 100% versus 44% and 84% (P = .003 andP = .07) in pts with the TNF-238G allele, respectively. These findings suggest that regulatory polymorphisms of the TNF-α gene can affect TNF-α production and predict the outcome after Thal therapy, particularly in those MM pts who are genetically defined as “high producers” of TNF-α. | ||
| 700 | 1 | |a Mytilineos, Joannis |e VerfasserIn |0 (DE-588)1076347819 |0 (DE-627)834742268 |0 (DE-576)166586900 |4 aut | |
| 700 | 1 | |a Möhler, Thomas |e VerfasserIn |0 (DE-588)1014877261 |0 (DE-627)705298051 |0 (DE-576)34979572X |4 aut | |
| 700 | 1 | |a Preiss, Astrid |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Opelz, Gerhard |d 1944- |e VerfasserIn |0 (DE-588)1026480345 |0 (DE-627)726772453 |0 (DE-576)371826527 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 100(2002), 6, Seite 2263-2265 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:100 |g year:2002 |g number:6 |g pages:2263-2265 |g extent:3 |a Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.V100.6.2263 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0006497120510343 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211210 | ||
| 993 | |a Article | ||
| 994 | |a 2002 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 8 |y j | ||
| 998 | |g 1026480345 |a Opelz, Gerhard |m 1026480345:Opelz, Gerhard |d 910000 |d 911600 |e 910000PO1026480345 |e 911600PO1026480345 |k 0/910000/ |k 1/910000/911600/ |p 7 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1014877261 |a Möhler, Thomas |m 1014877261:Möhler, Thomas |d 910000 |d 910100 |e 910000PM1014877261 |e 910100PM1014877261 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1076347819 |a Mytilineos, Joannis |m 1076347819:Mytilineos, Joannis |d 910000 |d 910100 |e 910000PM1076347819 |e 910100PM1076347819 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 120842181 |a Neben, Kai |m 120842181:Neben, Kai |d 910000 |d 910100 |e 910000PN120842181 |e 910100PN120842181 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1780935943 |e 4018504233 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma","title_sort":"Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma"}],"physDesc":[{"noteIll":"Diagramme","extent":"3 S."}],"relHost":[{"title":[{"subtitle":"journal of the American Society of Hematology","title_sort":"Blood","title":"Blood"}],"id":{"zdb":["1468538-3"],"eki":["266886647"],"issn":["1528-0020"]},"origin":[{"publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedDisp":"1946-","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedKey":"1946"}],"corporate":[{"display":"American Society of Hematology","role":"isb"}],"disp":"Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myelomaBlood","note":["Gesehen am 21.04.2023"],"titleAlt":[{"title":"Blood online"}],"pubHistory":["1.1946 -"],"part":{"extent":"3","pages":"2263-2265","year":"2002","issue":"6","text":"100(2002), 6, Seite 2263-2265","volume":"100"},"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"266886647","language":["eng"]}],"origin":[{"dateIssuedKey":"2002","dateIssuedDisp":"[15 September 2002]"}],"name":{"displayForm":["Kai Neben, Joannis Mytilineos, Thomas M. Moehler, Astrid Preiss, Alwin Kraemer, Anthony D. Ho, Gerhard Opelz, and Hartmut Goldschmidt"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1780935943"],"doi":["10.1182/blood.V100.6.2263"]},"recId":"1780935943","person":[{"role":"aut","family":"Neben","display":"Neben, Kai","given":"Kai"},{"display":"Mytilineos, Joannis","role":"aut","family":"Mytilineos","given":"Joannis"},{"family":"Möhler","role":"aut","display":"Möhler, Thomas","given":"Thomas"},{"role":"aut","family":"Preiss","display":"Preiss, Astrid","given":"Astrid"},{"given":"Alwin","family":"Krämer","role":"aut","display":"Krämer, Alwin"},{"given":"Anthony Dick","role":"aut","family":"Ho","display":"Ho, Anthony Dick"},{"role":"aut","family":"Opelz","display":"Opelz, Gerhard","given":"Gerhard"},{"given":"Hartmut","display":"Goldschmidt, Hartmut","role":"aut","family":"Goldschmidt"}],"language":["eng"],"note":["Gesehen am 10.12.2021"],"titleAlt":[{"title":"Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma"}]} | ||
| SRT | |a NEBENKAIMYPOLYMORPHI1520 | ||